TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7872387
Drug: Vehicle drops
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle drops from the fibronectin solution
Study: 2404368
Drug: Ceftazidime 500
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 500 mg twice daily for five days
Study: 2404368
Drug: Moxalactam 500
Normalized name: Moxalactam
DrugBank: Moxalactam (hydrolyzed) (DB04740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam 500 mg twice daily for five days
Study: 358727
Drug: Paracervical blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical blocks administered to PGF2alpha-treated patients
Study: 358727
Drug: No paracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No paracervical blocks administered to PGF2alpha-treated patients
Study: 358727
Drug: Paracervical blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical blocks administered to saline-treated patients
Study: 358727
Drug: No paracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No paracervical blocks administered to saline-treated patients
Study: 31339827
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy (physician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin)
Study: 26028929
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment for 4 weeks (n = 36)
Study: 26028929
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment for 8 weeks (n = 43)
Study: 26028929
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment for 12 weeks (n = 23)
Study: 26028929
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment for 4 weeks vs 12 weeks
Study: 26028929
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment for all periods
Study: 23818710
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment strategies (tight control)
Study: 23818710
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive treatment strategies
Study: 18942777
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment for rheumatoid arthritis
Study: 18942777
Drug: Existing treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing treatments
Study: 16963040
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: recombinant hFSH from day 3 until follicles reached 13‐14 mm, then lowered to 75 IU daily, with daily injections of 200 IU of hCG and a GnRH antagonist until final maturation
Study: 16963040
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: recombinant hFSH and a GnRH antagonist
Study: 16963040
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: recombinant hFSH and a GnRH agonist
Study: 14599958
Drug: Enzyme supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme supplementation therapy
Study: 1533455
Drug: Amoxicillin 25
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 25 mg/kg/day divided into two doses for 3 months
Study: 1533455
Drug: Glycoproteins from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoproteins from Klebsiella pneumoniae (GKP) 2 tablets per day during 8 days in the 1st month and 1 tablet per day during 8 days in the following 2 months
Study: 3889259
Drug: Intratracheal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal administration of human surfactant
Study: 3889259
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with intermittent mandatory ventilation
Study: 31557127
Drug: Oral aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aromatase inhibitors (AIs)
Study: 31557127
Drug: Subcutaneous daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous daily growth hormone (GH)
Study: 31557127
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (AI/GH)
Study: 8198064
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (500 mg, three times a day) for 5 of the 10 weeks
Study: 29982870
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion chemotherapy (HAIC)
Study: 26544615
Drug: Evidence-based decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based decision support for depression treatment
Study: 23989915
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2-3 mg/kg per day
Study: 23989915
Drug: Mesalazine 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 3.2 g per day
Study: 19270470
Drug: Day clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day clinic treatment
Study: 16549463
Drug: CLA-diet rich
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLA-diet rich in CLA (4.7 g/d of c9,t11- and t10,c12-CLA isomers in equal amounts)
Study: 16549463
Drug: VA-diet rich
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA-diet rich in VA (3.6 g/d)
Study: 8420411
Drug: Heparin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (25 U/kg) administered intravenously 10 min before challenge
Study: 8420411
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (20,000 units) administered 10 min before challenge
Study: 3310589
Drug: Moricizine HCl
Normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine HCl therapy
Study: 29862568
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention therapy combined with routine medications
Study: 15729225
Drug: Midazolam 7.5
Normalized name: midazolam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 7.5 mg orally
Study: 12893326
Drug: OXY‐TDS 3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXY‐TDS 3.9 mg/day
Study: 12893326
Drug: TOL‐LA 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL‐LA 4 mg/day
Study: 9467472
Drug: Piroxicam FDDF
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam FDDF (40 mg sublingual)
Study: 9467472
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg intramuscular)
Study: 7874912
Drug: Critical care
Normalized name: Adult critical care formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical care medicine elective consisting of orientation, interactive conferences, technical skills laboratories, daily rounds, and patient-care experience.
Study: 2089356
Drug: Naftidrofuryl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (2 x 200 mg/day for 6 weeks)
Study: 30219027
Drug: Scalp nerves
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine (Group LA)
Study: 30219027
Drug: Scalp nerves
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine plus 15 IU/ml Hyaluronidase (Group H)
Study: 27308644
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (esomeprazole 20 mg, twice daily)
Study: 27308644
Drug: Double-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose therapy (esomeprazole 40 mg, twice daily)
Study: 12464464
Drug: Amisulpride (400-1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400-1,000 mg/day)
Study: 2290711
Drug: Ceftriaxone (Cef)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (Cef) 2 g daily infusion
Study: 2290711
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) 2 g daily infusion
Study: 31961463
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus megestrol acetate (MA) - MA (160 mg orally, daily) plus metformin (500 mg orally, three times a day)
Study: 31961463
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) alone - MA (160 mg orally, daily)
Study: 31961463
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus MA in AEH patients
Study: 31961463
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus MA in non-obese AEH patients
Study: 31961463
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus MA in insulin-sensitive AEH patients
Study: 24225216
Drug: PCT monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT monitoring in guiding the use of antibiotics group (PCT group, n=42)
Study: 24225216
Drug: Regular antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular antibiotic therapy group (RAT group, n=40)
Study: 11377651
Drug: Local activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local activation of low-dose ifosfamide using encapsulated genetically modified allogeneic cells delivered by supraselective angiography
Study: 9517370
Drug: Gemfibrozil, 600
Normalized name: Gemfibrozil, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil, 600 mg twice daily
Study: 9517370
Drug: Lovastatin, 40
Normalized name: Lovastatin, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin, 40 mg daily
Study: 8278467
Drug: Siltex textured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltex textured inflatable implant
Study: 8278467
Drug: Smooth inflatable
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth inflatable implant
Study: 2662695
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (3 g/day)
Study: 27429374
Drug: Half-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose group (3 mg/m verteporfin, 83 seconds laser light)
Study: 27429374
Drug: Half-fluence group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-fluence group (6 mg/m verteporfin, 42 seconds laser light)
Study: 21910334
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment (insulin and anti-diabetic drugs)
Study: 6422900
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate or monoamine oxidase (MAO) inhibitors
Study: 6422900
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (TCA) and second-generation antidepressants
Study: 25286703
Drug: Ultrasound-guided facet
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided facet joint injection
Study: 25286703
Drug: Blindly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blindly administered facet joint block
Study: 22811444
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (85% cocoa, 0.55 g/kg body wt)
Study: 20600400
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 20% (w/w) HPMC
Study: 20600400
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 40% (w/w) HPMC
Study: 20600400
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with lower concentration of HPMC and higher lactose concentration
Study: 17646513
Drug: ropivacaine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.05% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Study: 17646513
Drug: ropivacaine 0.075%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.075% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Study: 17646513
Drug: ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.1% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Study: 16286872
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg(‐1) body mass)
Study: 12670087
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg minocycline hydrochloride (Arestin) administered at baseline, three and six months
Study: 7654482
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg once a day for 2 months
Study: 31684867
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine bolus 1.5 mg/kg at induction followed by an infusion (1.5 mg/kg/h)
Study: 31684867
Drug: IV esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV esmolol bolus 0.5 mg/kg at induction followed by an infusion (5-15 μg/kg/min)
Study: 26679480
Drug: Budesonide respules
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide respules via mucosal atomization device (MAD) twice daily
Study: 26679480
Drug: Budesonide respules
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide respules instilled via vertex-to-floor (VF) position twice daily
Study: 26679480
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray twice daily
Study: 23103035
Drug: Long-term PM(2.5)
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term PM(2.5) exposure (3 μg/m(3) increase)
Study: 23103035
Drug: Short-term PM(2.5)
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term PM(2.5) exposure (12 μg/m(3) daily increase)
Study: 17496489
Drug: Trimetazidine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine, 20 mg three times daily for 12 weeks
Study: 11977538
Drug: Dietary guidance
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary guidance and ingestion of aged garlic extract (AGE) capsules
Study: 11977538
Drug: Dietary guidance
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary guidance and non‐function capsules
Study: 9846676
Drug: Transdermal oestrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogens 50 microg, 2 patches/week for 3 weeks per month, plus acetate nomegestrolo per os 5 mg/die for 12 days per cycle (Group A)
Study: 9846676
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/die (Group B)
Study: 9846676
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Control Group C)
Study: 8137201
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy (CRT) - 20 Gy and two courses of 5-FU and cisplatin
Study: 1262709
Drug: Freshly harvested
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Freshly harvested vaccine (3 x 10(10)‐10(11) organisms/dose)
Study: 1262709
Drug: Fresh vaccine
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh vaccine
Study: 31169793
Drug: HIGH carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH carbohydrate intake (8 g·kg body mass)
Study: 31169793
Drug: LOW carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW carbohydrate intake (3 g·kg body mass)
Study: 23446963
Drug: Fortified food
Normalized name: fortified food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified food supplement (SG)
Study: 23446963
Drug: No food
Approvals — FDA: no, EMA: no, PMDA: no
Description: No food supplement (NSG)
Study: 21693443
Drug: Hyalograft‐3D autograft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyalograft‐3D autograft followed by Laserskin autograft after 2 weeks (treatment group)
Study: 18952009
Drug: Topical l-NAME
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical l-NAME (NO synthase inhibitor)
Study: 18952009
Drug: Inhalation
Normalized name: INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation
Study: 17227571
Drug: Losartan (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50-100 mg daily)
Study: 17227571
Drug: Carvedilol (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5-25 mg)
Study: 16083171
Drug: Continuous ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ultrasound therapy with intensity of 0.5 W/cm2 applied to the palmar carpal tunnel for 10 minutes, 5 days a week for 4 weeks.
Study: 16083171
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound and Diclofenac 75 mg/day in divided doses.
Study: 2418304
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (2.5 mg)
Study: 2418304
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (5 mg)
Study: 2418304
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (10 mg)
Study: 2418304
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (various doses)
Study: 21448918
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg plus vitamin D(3) 2800 IU (ALN + D)
Study: 16813472
Drug: Fractionated walking
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated walking (2 daily sessions)
Study: 12944249
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (100 g)
Study: 12944249
Drug: White chocolate
Normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White chocolate (100 g)
Study: 12944249
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (100 g)
Study: 1678316
Drug: Bopindolol (B)
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol (B) 2 mg once daily after initial 1 mg for 4 weeks
Study: 1678316
Drug: Diltiazem (D)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (D) 240 mg in 4 divided doses after initial 120 mg
Study: 26384091
Drug: Berberis aristata/Silybum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberis aristata/Silybum marianum (B. aristata/S. marianum) 588/105 mg, 1 tablet at lunch and 1 tablet at dinner for six months
Study: 26348588
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (psychoeducation plus medication)
Study: 25300245
Drug: Treatment-as-usual (medication)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (medication)
Study: 19642717
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine for 10 minutes (injection of local anesthetic)
Study: 9799060
Drug: Omeprazole treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole treatment (20 mg for 4 days) with enteric-coated sodium salicylate tablets
Study: 9799060
Drug: Uncoated acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated acetylsalicylic acid tablets
Study: 10517036
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20-minute sessions of shoulder, neck, head, and facial massage)
Study: 6347117
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal (group G)
Study: 25737375
Drug: Intravenous antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antimicrobial prophylaxis alone (control)